Dose escalation cohort: advanced and/or metastatic cancer car-cinoma of the breast, stomach, esophagus, pancreas, endometri-um, ovary or lung. Expansion cohort: HER2-expressing, i.e HER2-positive and HER2-low breast cancer

• FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Recruitment ended
  2023-504605-36-00 1 2022-01-21

Showing 1–1 of 1 trials